An enhanced chemopreventive effect of methyl donor S-adenosylmethionine in combination with 25-hydroxyvitamin D in blocking mammary tumor growth and metastasis.
Cancer
Journal
Bone research
ISSN: 2095-4700
Titre abrégé: Bone Res
Pays: China
ID NLM: 101608652
Informations de publication
Date de publication:
2020
2020
Historique:
received:
21
11
2019
revised:
05
04
2020
accepted:
10
05
2020
entrez:
28
7
2020
pubmed:
28
7
2020
medline:
28
7
2020
Statut:
epublish
Résumé
Therapeutic targeting of metastatic breast cancer still remains a challenge as the tumor cells are highly heterogenous and exploit multiple pathways for their growth and metastatic spread that cannot always be targeted by a single-agent monotherapy regimen. Therefore, a rational approach through simultaneous targeting of several pathways may provide a better anti-cancer therapeutic effect. We tested this hypothesis using a combination of two nutraceutical agents S-adenosylmethionine (SAM) and Vitamin D (Vit. D) prohormone [25-hydroxyvitamin D; '25(OH)D'] that are individually known to exert distinct changes in the expression of genes involved in tumor growth and metastasis. Our results show that both SAM and 25(OH)D monotherapy significantly reduced proliferation and clonogenic survival of a panel of breast cancer cell lines in vitro and inhibited tumor growth, lung metastasis, and breast tumor cell colonization to the skeleton in vivo. However, these effects were significantly more pronounced in the combination setting. RNA-Sequencing revealed that the transcriptomic footprint on key cancer-related signaling pathways is broader in the combination setting than any of the monotherapies. Furthermore, comparison of the differentially expressed genes from our transcriptome analyses with publicly available cancer-related dataset demonstrated that the combination treatment upregulates genes from immune-related pathways that are otherwise downregulated in bone metastasis in vivo. Since SAM and Vit. D are both approved nutraceuticals with known safety profiles, this combination treatment may serve as a novel strategy to reduce breast cancer-associated morbidity and mortality.
Identifiants
pubmed: 32714613
doi: 10.1038/s41413-020-0103-6
pii: 103
pmc: PMC7376160
doi:
Types de publication
Journal Article
Langues
eng
Pagination
28Subventions
Organisme : Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre (Skin Research Training Centre)
ID : 130410
Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsM.S. is the founder of HKG Epitherapeutics and Montreal EpiTerapia. All other authors declare no competing financial interests.
Références
Bioinformatics. 2015 Jan 15;31(2):166-9
pubmed: 25260700
Nat Med. 2012 Aug;18(8):1224-31
pubmed: 22820642
Nutr Cancer. 2012;64(7):919-28
pubmed: 22966878
Molecules. 2014 Apr 17;19(4):4924-40
pubmed: 24747649
Endocr Relat Cancer. 2013 Mar 22;20(2):R31-47
pubmed: 23319494
PLoS One. 2012;7(1):e29862
pubmed: 22238668
Am J Pathol. 2003 Nov;163(5):2113-26
pubmed: 14578209
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Antiviral Res. 1990 Oct-Nov;14(4-5):181-205
pubmed: 2088205
Nucleic Acids Res. 2013 Jan;41(Database issue):D793-800
pubmed: 23143270
Database (Oxford). 2015 Mar 28;2015:
pubmed: 25819073
Cell. 2015 Aug 27;162(5):974-86
pubmed: 26317466
Mol Pharmacol. 2009 Jul;76(1):192-200
pubmed: 19372210
Clin Cancer Res. 2005 May 1;11(9):3579-86
pubmed: 15867263
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Genome Biol. 2014;15(12):550
pubmed: 25516281
Pharmacotherapy. 2004 Nov;24(11):1501-7
pubmed: 15537554
Am J Clin Nutr. 2008 Aug;88(2):565S-569S
pubmed: 18689403
Br J Pharmacol. 2015 Jun;172(11):2705-15
pubmed: 25134627
CA Cancer J Clin. 2006 Jan-Feb;56(1):37-47; quiz 50-1
pubmed: 16449185
Genome Res. 2019 Jun;29(6):969-977
pubmed: 31160376
Br J Pharmacol. 2015 Jun;172(11):2769-81
pubmed: 25631332
Aging Cell. 2013 Feb;12(1):148-55
pubmed: 23157586
Nat Rev Cancer. 2007 Sep;7(9):684-700
pubmed: 17721433
Anticancer Res. 2014 Mar;34(3):1163-6
pubmed: 24596354
Adv Exp Med Biol. 2019;1164:179-196
pubmed: 31576549
Br J Psychiatry. 1989 Jan;154:48-51
pubmed: 2673478
Endocrinology. 2016 Jun;157(6):2204-16
pubmed: 27119753
Cancer Prev Res (Phila). 2015 Feb;8(2):120-8
pubmed: 25468832
Cancer Res. 2008 Aug 1;68(15):6251-9
pubmed: 18676849
Nutr Rev. 2007 Aug;65(8 Pt 2):S80-3
pubmed: 17867376
Mol Cancer Ther. 2017 Mar;16(3):494-505
pubmed: 28069877
Cancer. 1997 Oct 15;80(8 Suppl):1588-94
pubmed: 9362426
Nat Methods. 2015 Apr;12(4):357-60
pubmed: 25751142
Mol Cancer Ther. 2019 Mar;18(3):632-641
pubmed: 30587557
Nature. 2001 May 17;411(6835):342-8
pubmed: 11357141
Cancer Med. 2015 May;4(5):732-44
pubmed: 25619880
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Oncotarget. 2017 Dec 26;9(4):5169-5183
pubmed: 29435170
Carcinogenesis. 2014 Nov;35(11):2436-46
pubmed: 25178277
Biochem Biophys Res Commun. 2011 Apr 29;408(1):145-8
pubmed: 21463611
Br J Cancer. 1987 Jan;55(1):61-6
pubmed: 3814476
Breast Cancer Res. 2010;12(4):R56
pubmed: 20663194
Cell Host Microbe. 2015 Dec 9;18(6):723-35
pubmed: 26651948
N Engl J Med. 2019 Jan 3;380(1):33-44
pubmed: 30415629
Oncol Res. 2017 Apr 14;25(4):511-522
pubmed: 27733217